Focused On-demand Library for Actin-related protein 2/3 complex subunit 4

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We use our state-of-the-art dedicated workflow for designing focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

P59998

UPID:

ARPC4_HUMAN

Alternative names:

Arp2/3 complex 20 kDa subunit

Alternative UPACC:

P59998; C9JWM7; E7ETI0; F6TTL5; O15509; Q6P0W5; Q96QJ3

Background:

The Actin-related protein 2/3 complex subunit 4, also known as the Arp2/3 complex 20 kDa subunit, plays a pivotal role in cellular dynamics. It is an actin-binding component of the Arp2/3 complex, crucial for actin polymerization in response to nucleation-promoting factors. This process underpins the formation of branched actin networks in the cytoplasm, essential for cell motility, and also facilitates actin polymerization in the nucleus, impacting gene transcription and DNA repair.

Therapeutic significance:

Linked to Developmental delay, language impairment, and ocular abnormalities, the protein's involvement in this autosomal dominant disorder highlights its potential as a therapeutic target. Understanding the role of Actin-related protein 2/3 complex subunit 4 could open doors to potential therapeutic strategies.